Asimov
Asimov, a cellular engineering firm, advances biologics and gene therapy design through synthetic biology and AI tools.
Founded
2017Asimov, a cellular engineering firm, advances biologics and gene therapy design through synthetic biology and AI tools.
Asimov, founded in Boston, MA, is a pioneering cellular engineering company focused on advancing the design and manufacture of biologics and gene therapies. The company integrates mammalian synthetic biology, computer-aided design, and machine learning to develop sophisticated tools for programming living cells. Asimov's core mission is to revolutionize healthcare by creating innovative solutions that enhance the precision and efficacy of genetic treatments. Their product offerings include the CHO Edge System, LV Edge System, and AAV Edge System, targeting the biologics and gene therapy markets.
Notable figures affiliated with Asimov include a multi-disciplinary team of experts in synthetic biology and AI. The company has attracted significant interest from investors in the biotech sector, contributing to its rapid growth and development. Key achievements include the successful deployment of their Edge Systems, which have set new standards in genetic design and manufacturing. Asimov's impact is marked by its contributions to advancing therapeutic solutions, potentially transforming the landscape of modern medicine.
Companies similar to Asimov include AI Proteins, Think Bioscience, Absci and Synvivia.
Asimov was founded in 2017.
Asimov's headquarters is located in Boston, MA, US.
Asimov's most recent funding round was for $175M (USD) in January 2023.
As of Jan 5, 2023, Asimov has disclosed funding of $205M (USD). Undisclosed round amounts are excluded.
Asimov has 111 employees as of Feb 4, 2024.
Synvivia
synvivia.com
